Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Accounts Payables (2016 - 2025)

Historic Accounts Payables for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $76000.0.

  • NovaBay Pharmaceuticals' Accounts Payables fell 8080.81% to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76000.0, marking a year-over-year decrease of 8080.81%. This contributed to the annual value of $109000.0 for FY2024, which is 8796.91% down from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Accounts Payables stood at $76000.0 for Q3 2025, which was down 8080.81% from $604000.0 recorded in Q2 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Accounts Payables peaked at $1.6 million during Q1 2022, and registered a low of $76000.0 during Q3 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' median Accounts Payables value was $947000.0 (recorded in 2023), while the average stood at $890631.6.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Accounts Payables surged by 34711.54% in 2022 and then plummeted by 8796.91% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Accounts Payables stood at $1.0 million in 2021, then increased by 3.35% to $1.1 million in 2022, then fell by 16.11% to $906000.0 in 2023, then tumbled by 87.97% to $109000.0 in 2024, then crashed by 30.28% to $76000.0 in 2025.
  • Its Accounts Payables was $76000.0 in Q3 2025, compared to $604000.0 in Q2 2025 and $800000.0 in Q1 2025.